Chemotherapy agents

Chemotherapy agents represent a broad and diverse category of systemic medications designed to inhibit the growth and proliferation of cancerous cells by targeting the machinery of cell division (NCI, 2023). Unlike targeted therapies that interact with specific signaling proteins, traditional chemotherapy primarily acts on fundamental cellular components such as DNA, RNA, and microtubules to induce cell cycle arrest and programmed cell death (American Cancer Society, 2024). These agents are classified based on their specific chemical behavior and the phase of the cell cycle they interrupt, including DNA-crosslinking alkylators and antimetabolites that block nucleotide synthesis (StatPearls, 2024). Because chemotherapy focuses on rapidly dividing cells, it lacks high specificity for malignant tissue, frequently affecting healthy tissues with high turnover rates such as the bone marrow, hair follicles, and gastrointestinal lining (NIH, 2023). This lack of specificity results in the characteristic systemic toxicities associated with treatment, necessitating careful dosing and monitoring of patient biomarkers (PubMed, 2022). Despite the emergence of immunotherapy, chemotherapy remains a foundational component of oncological care, often used in adjuvant or neo-adjuvant settings to reduce tumor burden and improve survival outcomes across a wide array of cancers (NCI, 2023).

Other names

Antineoplastic agentsCytotoxic agentsCytostaticsCancer chemotherapyChemotherapeutic drugs

Chemotherapy agents exert their effects by disrupting the cell cycle of rapidly dividing cells through several distinct mechanisms: alkylating agents covalently bond to DNA to prevent strand separation; antimetabolites masquerade as nucleosides to inhibit DNA synthesis; topoisomerase inhibitors prevent the re-ligation of DNA strands during replication; and microtubule-targeting agents interfere with the mitotic spindle apparatus (StatPearls, 2024; NCI, 2023).